(+1)508-753-4822customer@yurogen.com
English
CUSTOM SERVICES
Inquiry
Mouse Monoclonal Antibody Development
Yurogen Biosystems has extensive expertise in mouse monoclonal antibody discovery and has successfully delivered more than 2,000 mouse mAbs. With broad experience across diverse target types and application scenarios, we provide mature, reliable, and high-quality mouse monoclonal antibody development solutions.
Building upon traditional hybridoma technology, Yurogen Biosystems has further integrated multiple cutting-edge technologies to establish several highly efficient mouse mAb discovery platforms. These include conventional hybridoma fusion combined with single-cell screening and culture platforms, and NGS-based high-throughput sequencing coupled with AI-assisted prediction algorithms for mouse mAb discovery.
These technology platforms enable the rapid and efficient identification of high-affinity and high-specificity monoclonal antibodies from both wild-type mice and human IgG transgenic mice. They significantly accelerate project timelines, improve success rates, and enhance overall R&D efficiency. Together with traditional hybridoma technology, these complementary approaches allow us to meet the diverse needs of our clients.
Building upon traditional hybridoma technology, Yurogen Biosystems has further integrated multiple cutting-edge technologies to establish several highly efficient mouse mAb discovery platforms. These include conventional hybridoma fusion combined with single-cell screening and culture platforms, and NGS-based high-throughput sequencing coupled with AI-assisted prediction algorithms for mouse mAb discovery.
These technology platforms enable the rapid and efficient identification of high-affinity and high-specificity monoclonal antibodies from both wild-type mice and human IgG transgenic mice. They significantly accelerate project timelines, improve success rates, and enhance overall R&D efficiency. Together with traditional hybridoma technology, these complementary approaches allow us to meet the diverse needs of our clients.
Service Features
AI‑assisted Prediction Algorithms
Leverage antibody sequence analysis to identify high-potential candidates.
High Positive Rate
Achieve up to 30% antigen-binding positive rate.
Rapid Immunization Schedule
Immunization as short as 21 days.
One Stop Service
Comprehensive services: hybridoma sequencing, recombinant antibody expression and antibody humanization, etc.
High Positive Rate
Successfully delivered more than 2,000 distinct mouse monoclonal antibody projects.
Rapid Immunization Schedule
Customized immunization, screening, and sorting strategies tailored to each individual project.
Procedure
Workflow
Rapid Hybridoma Platform for Mouse mAb Development
Phase I
Animal Immunization
- Mouse immunization
- Detection of Antiserum Titers
- Other Tests (Optional): WB, FACS, IF, IHC
10 Weeks
(Rapid schedule available for 4-5 weeks)
(Rapid schedule available for 4-5 weeks)
Phase II
Cell Fusion and Screening
- Cell Fusion & HAT Screening
- Antigen-specific hybridoma single cell sorting and culture
- Positive cell culture supernatant test: FACS, WB, IHC, blocking ELISA, etc. (optional)
4 Weeks
Phase III
Hybridoma Sequencing,
Construction, Production & Validation
Construction, Production & Validation
- Positive hybridoma clone sequencing to amplify VH & VL gene
- Subclone VH & VL into expression vector to generate full IgG expression plasmid
- Recombinant mouse mAb expression & affinity purification (Protein A/G)
- QC: ELISA, SDS-PAGE, SEC-HPLC (optional), MS (optional), etc.
4 Weeks
Final Deliverables:
- Expression plasmid encoding full-length mouse IgG gene
- Affinity purified mouse mAb (up to 1mg)
- Mouse hybridoma cell line (Optional)
- Final report
Total timeline
~18 weeks
~18 weeks
Single Cell NGS-AI Platform for Mouse mAb Development
Phase I
Animal Immunization
- Mouse immunization
- Detection of Antiserum Titers
- Other Tests (Optional): WB, FACS, IF, IHC
10 Weeks
(Rapid schedule available for 4-5 weeks)
(Rapid schedule available for 4-5 weeks)
Phase II
Cell Sorting and cDNA Library Construction, NGS Sequencing and Data Analysis
- Splenocytes isolation and antigen-specific B cell sorting
- Single cell cDNA library construction
- BCR Sequencing and bioinformatic analysis for NGS data
3-4 Weeks
Phase III
Recombinant Antibody Expression, QC and Screening
- High level expression vector construction of recombinant antibody
- Antibody expression in eukaryotic system and purification
- Antibody activity screening: ELISA, FACS, IF, IHC, affinity testing
3-4 Weeks
Final Deliverables:
- High level expression plasmid encoding full-length mouse IgG gene
- Affinity purified mouse mAb (up to 1mg)
- Final report
Total timeline
~16-18 weeks
~16-18 weeks
Case Studies
Flow Cytometry Mouse mAb
Antibody and AAV Protein Antigen
Antibody and Oligonucleotide
Mouse mAb-Antibody Development for FC Applications
Target: FGFR1
Using hybridoma technology, 541 positive clones were screened, out of which 6 were selected for subcloning and cell line establishment. After purifying the antibodies, 3 monoclonal antibodies were obtained that met the requirements for FC applications. Moreover, these three murine monoclonal antibodies specifically bind to human FGFR1 without recognizing human FGFR2.
